Welcome to our dedicated page for Denali Therapeut news (Ticker: DNLI), a resource for investors and traders seeking the latest updates and insights on Denali Therapeut stock.
Denali Therapeutics Inc. (NASDAQ: DNLI) is a biotechnology and biopharmaceutical company developing product candidates engineered to cross the blood-brain barrier for the treatment of neurodegenerative diseases, lysosomal storage diseases and other serious conditions. This news page aggregates company-reported updates, press releases and related market announcements about Denali’s programs and corporate activities.
Readers can find coverage of Denali’s investigational enzyme replacement therapy tividenofusp alfa (DNL310) for Hunter syndrome (MPS II), including milestones related to its Biologics License Application, Priority Review status and the ongoing Phase 2/3 COMPASS study. News items also describe clinical and regulatory progress for other TransportVehicle™-enabled programs such as DNL126 (ETV:SGSH) for Sanfilippo syndrome type A, DNL952 (ETV:GAA) for Pompe disease, and TV-enabled antibody and oligonucleotide programs for Alzheimer’s and Parkinson’s disease.
In addition to pipeline updates, Denali’s releases discuss collaborations with partners such as Biogen, Takeda and Sanofi, a royalty funding agreement with Royalty Pharma tied to future net sales of tividenofusp alfa, and financial results reflecting research and development spending and launch preparations. Corporate governance and leadership changes, board appointments and participation in healthcare and investor conferences are also reported.
Investors and followers of DNLI can use this page to review historical and recent announcements on clinical trial progress, regulatory interactions, financing transactions and strategic partnerships as disclosed by the company in its public communications.
Denali Therapeutics (NASDAQ: DNLI) announced promising clinical results for DNL343 and SAR443820, investigational treatments for amyotrophic lateral sclerosis (ALS). A Phase 1 study of DNL343, which activates eIF2B, showed it was well-tolerated and achieved biomarker goals. The FDA granted Fast Track designation for SAR443820, a RIPK1 inhibitor, paving the way for a Phase 2 trial in early 2022. These advancements are critical as ALS lacks effective treatments, and both compounds target pathways involved in the disease's progression.
Denali Therapeutics (NASDAQ: DNLI) will present results from a Phase 1 healthy volunteer study of its EIF2B activator DNL343 at the upcoming 2021 Annual NEALS Meeting on October 6-7. DNL343 is currently in a Phase 1b study for ALS. Sanofi, Denali's partner, will also share plans for a Phase 2 study of RIPK1 inhibitor SAR443820. The webinar for analysts and investors will take place on October 6 at 4:30 p.m. ET, covering developments in ALS and frontotemporal dementia.
Denali Therapeutics announced the appointment of Katie Peng as Chief Commercial Officer to enhance its commercial strategy for neurodegenerative diseases. Ms. Peng, formerly at Genentech with $14 billion revenue responsibility, brings extensive experience in launching successful treatments for neurological and rare diseases. Her leadership is expected to advance Denali's clinical pipeline, including therapies for Parkinson's disease and Hunter syndrome. CEO Ryan Watts emphasized the strategic importance of her role in developing Denali's commercial organization.
Denali Therapeutics (NASDAQ: DNLI) has initiated dosing in a Phase 1b study of DNL343, a potential first-in-class treatment for amyotrophic lateral sclerosis (ALS). This study aims to evaluate the safety and efficacy of DNL343, which activates EIF2B, a protein complex crucial for neuronal health. ALS currently affects over 20,000 people in the U.S. annually. Denali plans to present preliminary data at the upcoming NEALS Meeting on October 6, 2021, highlighting the treatment’s significance for addressing critical unmet medical needs in ALS.
Denali Therapeutics (NASDAQ: DNLI) published preclinical findings demonstrating the efficacy of its Protein Transport Vehicle (PTV) in enhancing brain uptake of progranulin. This approach shows promise for treating frontotemporal dementia (FTD), particularly FTD-GRN, resulting from progranulin deficiency. The study, published in Cell, indicates that PTV:PGRN improves lysosomal function and addresses neurodegeneration in mouse models. Denali aims to initiate clinical testing for lead candidate DNL593, highlighting the potential therapeutic significance of its PTV technology.
Denali Therapeutics reported Q2 2021 financial results, showcasing a net loss of $60.7 million, slightly up from $58.8 million in Q2 2020. Collaboration revenue surged to $22.9 million, up from $5.8 million, primarily due to a $15 million milestone from Sanofi's Phase 2 study of DNL758. Significant progress was highlighted in the development of DNL310 for Hunter syndrome, demonstrating promising interim data in patient cohorts. Denali is set to initiate further clinical studies in ALS and Parkinson's disease by year-end 2021, with cash reserves approximating $1.4 billion.
Denali Therapeutics (NASDAQ: DNLI) reported positive interim results from its Phase 1/2 study of ETV:IDS (DNL310), a treatment for Hunter syndrome (MPS II). Findings showed a rapid reduction of heparan sulfate levels in cerebrospinal fluid (CSF) and significant clinical improvements in symptoms, cognitive and physical abilities. Safety data indicated a profile consistent with standard enzyme replacement therapy, with infusion-related reactions being the most common adverse events. Denali plans to initiate a pivotal Phase 2/3 study in the first half of 2022, indicating strong forward momentum for DNL310.
Denali Therapeutics (NASDAQ: DNLI) announced its participation in the MPS 2021 symposium, showcasing DNL310, an innovative brain-penetrant enzyme replacement therapy for Hunter syndrome. The company will present interim 24-week results from a Phase 1/2 study on July 25, 2021, followed by a webinar for analysts and investors. DNL310 aims to address the limitations of current treatments that don't effectively cross the blood-brain barrier. Denali's research efforts are significant for patients and families affected by this rare disease.
Denali Therapeutics (NASDAQ: DNLI) announced that its partner Sanofi has begun dosing in a Phase 2 trial of DNL758 for cutaneous lupus erythematosus (CLE). This small molecule inhibitor targets RIPK1, a protein involved in inflammation regulation. Denali will receive a $15 million milestone payment for this study, while Sanofi handles all development costs. Denali's collaboration with Sanofi, initiated in October 2018, aims to develop various RIPK1 inhibitors for neurodegenerative diseases. The trial results could significantly impact both companies' future prospects.
Denali Therapeutics Inc. (NASDAQ: DNLI) reported its Q1 2021 financial results, showing a net loss of $70 million, up from $56.8 million in Q1 2020.
Collaboration revenue increased to $7.9 million, driven by a rise in partnered program costs. R&D expenses rose to $60.2 million, influenced by higher personnel costs and pipeline investments. However, G&A expenses also increased to $18.9 million. Denali's cash position remains robust at $1.45 billion as of March 31, 2021. Key milestones were achieved for DNL310 in Hunter syndrome and DNL151 for Parkinson's, with several ongoing clinical studies.